首站-论文投稿智能助手
典型文献
Advances in Chinese medicine treatment and research on endocrine diseases in 2021
文献摘要:
This paper reviews the progress in treatment regimens involving traditional Chinese medicine and research on common clinical endocrine diseases in 2021, to provide a reliable basis for the traditional Chinese medicine treatment of endocrine diseases. In 2021–2022, research on traditional Chinese medicine for endocrine diseases has been focused on pathogenesis. We have summarized the results of the use of traditional Chinese medicine and herbal extracts for treating common endocrine system diseases in 2021, focusing on the following aspects. (1) Chinese herbal extracts or active ingredients, such as echinatin, breviscapine, and puerarin, can treat metabolic-associated fatty liver disease by inhibiting inflammation and oxidative stress, improving lipid metabolism, and regulating intestinal flora. (2) Chinese herbal extracts or active ingredients, such as Juglandis Semen extracts, Momordica charantia saponins, and Anemarrhenae Rhizoma extracts can treat type 2 diabetes by reducing insulin resistance, improving pancreatic beta cell function, and regulating intestinal microbial disorders. (3) Chinese herbal extracts or active ingredients, such as berberine, astragaloside IV, and Scutellariae Barbatae Herba polysaccharides, can treat diabetes-related complications by improving mitochondrial function, regulating autophagy, and inhibiting apoptosis and pyroptosis. (4) Chinese herbal medicines and herbal extracts or active ingredients, such as berberrubine and Resedaodorata, can treat hyperuricemia by activating the Janus kinase 2/signal transducers and activators of transcription 3 signaling pathway and inhibiting toll-like receptor 4/NOD-like receptor family, pyrin domain-containing protein 3 signaling to increase urate excretion. (5) Herbal extracts or active ingredients, such as ginsenoside Rb1, corylin, and Scutellariae Radix polysaccharides, can exert anti-obesity effects by promoting the browning of white adipocytes, activation of brown adipose tissue, and regulation of intestinal flora. (6) Chinese herbal extracts or active ingredients, such as diosgenin and Prunellae Spica extract, are able to treat thyroid-related diseases by inhibiting nucleotide-binding oligomerization domain-like receptor protein 3 inflammatory vesicle activation, regulating the expression of proliferating cell nuclear antigen, and cadherin 1, and upregulating the ubiquitination of interferon regulatory factor 4.
文献关键词:
作者姓名:
Bao-Chao Pan;Hui Zhang;Han-Zhou Li;En-Ze Yuan;Jun-Yu Luo;Ting-Rui Zhang;Shu-Quan Lv;Wei-Bo Wen;Huan-Tian Cui
作者机构:
Hebei University of Traditional Chinese Medicine,Shijiazhuang 050091,China;Chengde Medical College,Chengde 067000,China;The First Clinical Medical College of Yunnan University of Traditional Chinese Medicine,Kunming 650500,China;Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Hebei University of Traditional Chinese Medicine,Cangzhou 061001,China;The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine,Kunming 650021,China;School of Life Sciences,Shandong University,Qingdao 266000,China
引用格式:
[1]Bao-Chao Pan;Hui Zhang;Han-Zhou Li;En-Ze Yuan;Jun-Yu Luo;Ting-Rui Zhang;Shu-Quan Lv;Wei-Bo Wen;Huan-Tian Cui-.Advances in Chinese medicine treatment and research on endocrine diseases in 2021)[J].传统医学研究(英文版),2022(05):82-95
A类:
breviscapine,Juglandis,Anemarrhenae,Scutellariae,Barbatae,berberrubine,Resedaodorata,corylin,Prunellae,Spica
B类:
Advances,Chinese,treatment,research,endocrine,diseases,This,paper,reviews,progress,regimens,involving,traditional,common,clinical,provide,reliable,basis,In,has,been,focused,pathogenesis,We,have,summarized,results,herbal,extracts,treating,system,focusing,following,aspects,active,ingredients,such,echinatin,puerarin,can,metabolic,associated,fatty,liver,by,inhibiting,inflammation,oxidative,stress,improving,lipid,metabolism,intestinal,flora,Semen,Momordica,charantia,saponins,Rhizoma,type,diabetes,reducing,insulin,resistance,pancreatic,beta,cell,function,microbial,disorders,berberine,astragaloside,IV,polysaccharides,related,complications,mitochondrial,autophagy,apoptosis,pyroptosis,medicines,hyperuricemia,activating,Janus,kinase,transducers,activators,transcription,signaling,pathway,toll,like,receptor,NOD,family,pyrin,domain,containing,protein,increase,urate,excretion,Herbal,ginsenoside,Rb1,Radix,exert,obesity,effects,promoting,browning,white,adipocytes,activation,adipose,tissue,regulation,diosgenin,are,thyroid,nucleotide,binding,oligomerization,inflammatory,vesicle,expression,proliferating,nuclear,antigen,cadherin,upregulating,ubiquitination,interferon,regulatory
AB值:
0.472738
相似文献
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD:A promising drug Potentilla discolor Bunge
Longshan Ji;Qian Li;Yong He;Xin Zhang;Zhenhua Zhou;Yating Gao;Miao Fang;Zhuo Yu;Robim M.Rodrigues;Yueqiu Gao;Man Li-Laboratory of Cellular Immunity,Institute of Clinical Immunology,Shanghai Key Laboratory of Traditional Chinese Medicine,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Key Laboratory of Liver and Kidney Diseases(Shanghai University of Traditional Chinese Medicine),Ministry of Education,Shanghai 201203,China;Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Department of Hepatopathy,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of in Vitro Toxicology and Dermato-Cosmetology,Faculty of Medicine and Pharmacy,Vrije Universiteit Brussel,Brussels 1000,Belgium
Ginsenoside Rb1 alleviates diabetic kidney podocyte injury by inhibiting aldose reductase activity
Jia-yi He;Quan Hong;Bi-xia Chen;Shao-yuan Cui;Ran Liu;Guang-yan Cai;Jiao Guo;Xiang-mei Chen-Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing 100853, China;Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Institute of Chinese Medicine, Guangdong Pharmaceutical University;Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou 510006, China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。